Technology | May 15, 2014

Mobile App Provides Life-Saving Assistance For Cardiac Patients

CathMaps+ debuts in Boston at AARP's Health [email protected]+ Tech Expo

CathMaps+ App Cath Lab Patient Engagement Mobile Devices

May 15, 2014 — CathMaps demonstrated how mobile technology can provide emergency assistance and peace of mind to millions of Americans at risk for a cardiac event. The AARP Health [email protected]+ Tech Expo showcases the latest in digital health technology designed to improve quality of life. The event is part of AARP's [email protected]+ National Event in Boston, May 8-10.

CathMaps+ is the world's first mobile application for people with elevated risk of a cardiac incident — particularly those who have a history of cardiac issues — that integrates critical health history and medical records with an interactive map of catheterization facilities (cath labs) throughout the world. The app is also HIPPA compliant.

"With the levels of heart disease on the rise in the U.S., the medical community must remain vigilant in our efforts to provide patients with tools and information that can help improve the quality of their lives," says Jack Stroh, an interventional cardiologist at Robert Wood Johnson University Hospital and St. Peter's University Hospital in New Jersey, and advisor to CathMaps+.

Approximately 715,000 Americans have a heart attack each year, according to the Centers for Disease Control. Nearly 30 percent of those have already suffered a heart attach. The CathMaps+ app ensures that patients quickly locate and are directed to a medical facility with a catheterization lab — wherever they may be traveling. They can securely access and share their medical history with the lab staff, saving critical time in treatment. They can also give permission for their information to be shared with loved ones, caregivers or emergency professionals.

"As a life or death condition, the idea of suffering a repeat incident is an almost constant concern. This app offsets patient anxiety, giving them peace of mind as they go about their daily lives," says Danny Oberman, founder and CEO of CathMaps+. "We see this as a valuable tool for cardiologist and the medical community as well. The AARP Health [email protected]+ Tech Expo is the perfect event to debut the app in the U.S."

Oberman founded CathMaps+ following his own cardiac incident in 2013. He combined his experience of living with an elevated risk of heart attack with his technology expertise to create a tool that is easy to use and functional in an emergency, while alleviating anxiety for cardiac patients.

CathMaps+, an Israeli-based technology company, is owned by Kickstart LLC, and is available for most Android and iOS users. The app is available in English and Spanish, with additional languages releases throughout 2014. It may be purchased from the App Store and Google Play.

For more information: www.cathmaps.com

Related Content

Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
Medtronic, CoreValve Evolut R TAVR system, U.S. IDE Study, TCT 2016
News | Heart Valve Technology| November 03, 2016
Medtronic plc unveiled new clinical data showing that patients treated with the self-expanding CoreValve Evolut R...
congenital heart patients, cardiac cath lab, anesthesia sedation practices, joint document, SCAI, SPA, CCAS
News | Congenital Heart| November 03, 2016
The Society for Cardiovascular Angiography and Interventions (SCAI), the Society for Pediatric Anesthesia (SPA) and the...
open-heart surgery, PCI, percutaneous coronary intervention, NOBLE trial, left main coronary artery disease, LMCAD, TCT 2016
News | Cardiovascular Surgery| November 03, 2016
Coronary artery bypass (CABG) surgery is the standard treatment for revascularization in patients with left main...
SENTINEL trial, transcatheter embolic protection, TCEP, TAVR, stroke, TCT 2016
News | Embolic Protection Devices| November 03, 2016
An international study has found that transcatheter cerebral embolic protection (TCEP) is safe, provides effective...
News | Drug-Eluting Balloons| November 03, 2016
The Spectranetics Corp. announced that it has submitted to the U.S. Food & Drug Administration (FDA) its Pre-Market...
RESPECT trial, Amplatzer PFO Occluder, St. Jude Medical, TCT 2016
News | Structural Heart Occluders| November 02, 2016
St. Jude Medical Inc. announced the long-term data from RESPECT, a landmark trial, during a First Report session at the...
Medtronic, Resolute Integrity DES, drug-eluting stent, BIO-RESORT study, TCT 2016
News | Stents Drug Eluting| November 02, 2016
Investigators recently unveiled clinical data from the independent BIO-RESORT study, representing the first all-comers...
Medtronic, Harmony TPV, transcatheter pulmonary valve, clinical study results, TCT 2016
News | Heart Valve Technology| November 02, 2016
Medtronic plc recently announced new clinical data for the Harmony Transcatheter Pulmonary Valve (TPV) from its early...
St. Jude Medical, Amplatzer PFO Occluder, FDA approval, U.S. launch
Technology | Structural Heart Occluders| November 02, 2016
St. Jude Medical Inc. announced this week the U.S. Food and Drug Administration (FDA) approval and launch of the...
Overlay Init